Pharmacological Reviews

Pharmacological Reviews is a quarterly peer-reviewed review journal published by the American Society for Pharmacology and Experimental Therapeutics in partnership with Elsevier, established in 1949 and covering the whole spectrum of pharmacology, with a 2025 Journal Impact Factor of 20.3《药理学评论》是由（American Society for Pharmacology and Experimental Therapeutics）与（Elsevier）合作出版、1949 年创刊的季刊同行评审综述期刊，涵盖药理学的整个领域，2025 年影响因子为 20.3。

Scope

• It presents in-depth review articles covering the broad spectrum of pharmacology, including biochemical and cellular pharmacology, drug metabolism and disposition, renal pharmacology, neuropharmacology, behavioral pharmacology, clinical pharmacology and toxicology该刊刊载覆盖药理学广泛领域的深度综述，包括生化与细胞药理学、药物代谢与处置、肾脏药理学、神经药理学、行为药理学、临床药理学与毒理学。
• It is the official venue for the nomenclature reports of the International Union of Basic and Clinical Pharmacology, which standardize receptor and drug target naming该刊是（International Union of Basic and Clinical Pharmacology）命名报告的官方发布平台，用于规范受体与药物靶点的命名。
• The journal focuses on authoritative reviews of trending topics rather than on primary research papers该刊专注于对热点主题的权威综述，而非原创研究论文。
• Its content is aimed at pharmacologists, medicinal chemists, toxicologists and translational researchers across academia, industry and regulatory bodies其内容面向学术界、产业界与监管机构的药理学家、药物化学家、毒理学家与转化研究者。
• Topics range from receptor pharmacology and signal transduction to pharmacokinetics, pharmacogenomics and drug safety选题范围从受体药理学与信号转导，延伸到药代动力学、药物基因组学与药物安全性。
• It ranks among the leading titles in the pharmacology and pharmacy category of the Journal Citation Reports该刊在期刊引证报告的药理学与药学类别中位居前列。

History

• The journal was founded in 1949 under the joint auspices of the American Society for Pharmacology and Experimental Therapeutics, the British Pharmacological Society and the Scandinavian Pharmacological Society该刊于 1949 年由（American Society for Pharmacology and Experimental Therapeutics）、（British Pharmacological Society）与（Scandinavian Pharmacological Society）共同创办。^[1]
• Volumes 1 and 2 were issued as part 2 of the final number of each volume of the Journal of Pharmacology and Experimental Therapeutics, and it became an independent title in 1951其第 1、2 卷曾作为（Journal of Pharmacology and Experimental Therapeutics）各卷末期的第 2 部分出版，1951 年起独立成刊。
• It was originally a quarterly review series and now publishes articles continuously online, with papers then assigned to quarterly issues该刊最初为季度综述系列，如今在线上持续发表论文，随后再将论文归入季度期次。
• From 2023 the journals of the society, including Pharmacological Reviews, have been published in collaboration with Elsevier自 2023 年起，该学会旗下包括《药理学评论》在内的期刊与（Elsevier）合作出版。
• Its impact factor moved from 25.468 in 2021 and 17.3 in 2024 to 20.3 in 2025其影响因子由 2021 年的 25.468、2024 年的 17.3 变化到 2025 年的 20.3。
• Articles become freely accessible one to five years after publication, while nomenclature reports are free upon publication论文在发表一到五年后可免费获取，而命名报告自发表起即免费开放。

Editors

• Its Editor-in-Chief is Lynette C. Daws, a professor at the University of Texas Health Science Center at San Antonio and the first female editor of the journal现任主编为 Lynette C. Daws，得克萨斯大学圣安东尼奥健康科学中心教授，也是该刊首位女性主编。
• Her predecessors as editor include Eric Barker and David R. Sibley of the National Institute of Neurological Disorders and Stroke其前任主编包括 Eric Barker 与（National Institute of Neurological Disorders and Stroke）的 David R. Sibley。
• David R. Sibley served a long term as Editor-in-Chief and recruited both Eric Barker and Lynette Daws to lead the journalDavid R. Sibley 曾长期担任主编，并招募 Eric Barker 与 Lynette Daws 接续领导该刊。
• The journal is supported by a team of associate editors and an international editorial board of pharmacologists该刊由副编辑团队与由药理学家组成的国际编委会支持。
• All review articles are peer reviewed, and manuscript handling is described in the journal's instructions to authors所有综述均经同行评审，稿件处理流程在期刊作者须知中有说明。
• The editorial office works with staff of the society and of Elsevier on production, operations and marketing of the journal编辑部与该学会及（Elsevier）的工作人员协作完成该刊的生产、运营与推广。